Clinical Trial: Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07737249) titled 'Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease' on July 27.

Brief Summary: The goal of this clinical trial is to learn whether adding the JAK inhibitor golidocitinib to standard corticosteroid therapy works to treat rapidly progressive interstitial lung disease (RP-ILD) in patients with acute worsening. It will also learn about its safety compared to standard treatment without JAK inhibitors (i.e., corticosteroids plus other immunosuppressants such as mycophenolate mofetil, tacrolimus, cyclophosphamide, or biologics).

The main questions it aims to answer are:

* How much does the addition of ...